Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date)
Access Pharmaceuticals Inc. (AMEX:AKC) RHEI Pharmaceuticals Inc. Agreement to market MuGard in China and certain other Southeast Asian countries RHEI will be responsible for marketing the product in China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam, and will handle manufacturing and regulatory activities for those areas (1/14)
Alfacell Corp. (ACEL) BL&H Co. Ltd. (South Korea) Distribution agreement for the commercialization of Onconase (ranpirnase) in South Korea, Taiwan and Hong Kong Alfacell granted BL&H exclusive rights to those areas for marketing, sales and distribution; Alfacell has received an up-front fee of $100,000 and is eligible for milestone payments; Alfacell also will receive 50% of all net sales in the territory (1/22)
Alkermes Inc. (ALKS) Cilag GmbH (subsidiary of Johnson & Johnson) Exclusive agreement to commercialize Vivitrol (naltrexone for extended-release injectable suspension) in alcohol and opioid dependence in Russia and other countries in the Commonwealth of Independent States Cilag will pay up-front fees and milestones up to $39M, plus ongoing royalties on Vivitrol sales in those regions; Alkermes will retain exclusive development and marketing rights to Vivitrol in all markets outside the U.S., Russia and CIS (1/7)
Anesiva Inc. (ANSV) Sigma-Tau SpA (Italy) Agreement granting an exclusive license to Sigma-Tau for the marketing and distribution of Anesiva's Zingo powder intradermal injection system in six European countries: Italy, France, Germany, Netherlands, Belgium and Luxembourg The deal includes an up-front payment to Anesiva and transfer price, as well as milestone payments (2/12)
Auriga Laboratories Inc. (OTC BB:ARGA) Middlebrook Pharmaceuticals Inc. Co-promotion agreement under which Auriga will co-promote Keflex 750-mg capsules to primary care specialists in the U.S. Financial terms were not disclosed (1/7)
Biovail Laboratories International SRL (subsidiary of Biovail Corp.; NYSE:BVF) Janssen Pharmaceutica NV (division of Johnson & Johnson) Exclusive supply agreement to market and distribute its once-daily, extended-release formulation of tramadol hydrochloride in 86 countries in Central and Eastern Europe/Middle East and Latin America Under terms of the 10-year deal, Biovail will manufacture the tablets in three dosage strengths and supply them to Janssen at contractually determined prices; Janssen will handle related promotional costs, as well as regulatory filings (1/2)
InSite Vision (AMEX:ISV) Shin Poong Pharm Co. Ltd. (Korea) Licensing and distribution agreement outside North America for its AzaSite 1% Shin Poong Pharm is responsible for regulatory approval and marketing in Korea; it will pay a double-digit royalty on net sales of AzaSite in Korea; InSite Vision is responsible for providing manufactured product (12/20)
Labopharm Inc. (Canada; DDSS) iNova Pharmaceuticals Pty Ltd. (Australia) Marketing and distribution agreement of once-daily tramadol in Australia Financial terms were not disclosed (1/25)
Paladin Labs Inc. (Canada; TSX:PLB) Nycomed (Switzerland) Canadian co-promotion agreement for Tridural once-daily tramadol Nycomed Canada will share brand responsibilities and expenses with Paladin and will deploy a sales force to promote the product; Paladin will continue to handle distribution and will continue promoting it using its primary care sales force (2/1)
Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the

Nasdaq market.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.